SCHEMBL481000

SCHEMBL481000

[O]Cc1ccccc1C(F)(F)F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.55
KMT2A Q03164 1/20 0.47
POLQ O75417 1/20 0.46
ALDH1A1 P00352 3/20 0.46
KDM4E B2RXH2 2/20 0.46
ATM Q13315 1/20 0.46
TDP1 Q9NUW8 3/20 0.45
DAO P14920 1/20 0.45
MAOB P27338 3/20 0.44
AR P10275 1/20 0.44
MAOA P21397 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
POLB P06746 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA9 Q16790 1/20 0.42
RECQL P46063 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC8 Q9BY41 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1043985 0.82 IDO1 (0.52) IDO1KMT2APOLQALDH1A1KDM4E
SCHEMBL18242814 0.82 IDO1 (0.38) IDO1KMT2APOLQALDH1A1KDM4E
SCHEMBL23337251 0.81 IDO1 (0.55) IDO1KMT2APOLQALDH1A1KDM4E
SCHEMBL239404 0.81 IDO1 (0.55) IDO1KMT2APOLQALDH1A1KDM4E
SCHEMBL1607335 0.80 AKR1B1 (0.46) IDO1KMT2AKDM4E
SCHEMBL17329111 0.80 IDO1 (0.59) IDO1KMT2APOLQALDH1A1KDM4E
SCHEMBL3647884 0.80 IDO1 (0.59) IDO1KMT2APOLQALDH1A1KDM4E
Ammonia Solution, Strong SCHEMBL267005 0.79 IDO1 (0.53) IDO1KMT2APOLQALDH1A1KDM4E
SCHEMBL18241965 0.79 IDO1 (0.36) IDO1KMT2APOLQALDH1A1KDM4E
SCHEMBL1043968 0.79 HDAC1 (0.51) IDO1KMT2APOLQALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11667638-B2 4-substitued cytisine analogues THE UNIVERSITY OF BRISTOL 2023-06-06 US claimed
EP-4112620-A1 CYTISINE DERIVATIVES FOR THE TREATMENT OF ADDICTION The University of Bristol (GB) 2023-01-04 EP claimed
US-20200172544-A1 COMPOUNDS THE UNIVERSITY OF BRISTOL (GB) 2020-06-04 US claimed
EP-3500572-A2 CYTISINE DERIVATIVES FOR THE TREATMENT OF ADDICTION The University Of Bristol (GB) 2019-06-26 EP claimed
WO-2018033742-A2 COMPOUNDS THE UNIVERSITY OF BRISTOL (GB) 2018-02-22 WO claimed
WO-2009080835-A1 THYROMIMETRIC COMPOUNDS IN TREATMENT OF DISEASE RELATED TO SONIC HEDGEHOG SIGNALLING KARO BIO AB (SE) 2009-07-02 WO claimed
US-20050137220-A1 Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors PHARMACIA CORPORATION (US) 2005-06-23 US claimed
EP-1063235-B1 BENZOFURYLPYRONE DERIVATIVES TEIJIN LTD (JP) 2004-05-12 EP claimed
EP-1351686-A2 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIDINES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE Pharmacia Corporation (US) 2003-10-15 EP claimed
US-20030186976-A1 Benzofurylpyrone derivatives TEIJIN LIMITED, MICROBIAL CHEMISTRY RESEARCH FOUNDATION 2003-10-02 US claimed
JP-2002500225-A 2002-01-08 JP claimed
WO-2001087842-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIDONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE PHARMACIA CORPORATION (US) 2001-11-22 WO claimed
JP-3187838-B2 2001-07-16 JP claimed
EP-1063235-A1 BENZOFURYLPYRONE DERIVATIVES TEIJIN LIMITED (JP) 2000-12-27 EP claimed
EP-1047694-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2000-11-02 EP claimed
WO-1999035146-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 1999-07-15 WO claimed
EP-0737195-A1 NEW GINKGOLIDE DERIVATIVES AND A PROCESS FOR PREPARING THEM SUNKYONG INDUSTRIES CO., LTD. (KR) 1996-10-16 EP claimed
US-5541183-A RESPIRATORY SYSTEM DISORDERS, SKIN DISORDERS AND PLATELET ACTIVATING FACTOR ANTAGONIST SUNKYONG INDUSTRIES CO., LTD. (KR) 1996-07-30 US claimed
WO-1995018131-A1 NEW GINKGOLIDE DERIVATIVES AND A PROCESS FOR PREPARING THEM SUNKYONG INDUSTRIES CO., LTD. (KR) 1995-07-06 WO claimed
US-4009277-A 1,2-Dialkyl-3,4,5-trisubstituted pyrazolium salts as fungicidal agents AMERICAN CYANAMID COMPANY (US) 1977-02-22 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137220-A1 Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors MAPKAPK2, MAP4K2, MAP3K2 IDO1 1691/4885KMT2A 500/4885POLQ 1721/4885
US-11667638-B2 4-substitued cytisine analogues CES2, CDA, PCYT1A IDO1 2029/4885KMT2A 976/4885POLQ 257/4885
US-20030186976-A1 Benzofurylpyrone derivatives PLIN5, ACSL5, PLIN1 IDO1 4305/4885KMT2A 4009/4885POLQ 4046/4885
US-20200172544-A1 COMPOUNDS CES2, CYCS, CHKB IDO1 2019/4885KMT2A 2166/4885POLQ 489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.